These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 28953602)

  • 1. Dementia with Lewy bodies: cerebrospinal fluid suppresses neuronal network activity.
    Theiss S; Maetzler W; Deuschle C; Lerche H; Koch H; Dihné M
    Neuroreport; 2017 Nov; 28(16):1061-1065. PubMed ID: 28953602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease.
    van der Zee S; Vermeiren Y; Fransen E; Van Dam D; Aerts T; Gerritsen MJ; Spikman JM; van Laar T; De Deyn PP
    J Parkinsons Dis; 2018; 8(1):71-84. PubMed ID: 29480224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
    Kaerst L; Kuhlmann A; Wedekind D; Stoeck K; Lange P; Zerr I
    J Alzheimers Dis; 2014; 38(1):63-73. PubMed ID: 23948928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies.
    Stuendl A; Kunadt M; Kruse N; Bartels C; Moebius W; Danzer KM; Mollenhauer B; Schneider A
    Brain; 2016 Feb; 139(Pt 2):481-94. PubMed ID: 26647156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies.
    Chatterjee M; van Steenoven I; Huisman E; Oosterveld L; Berendse H; van der Flier WM; Del Campo M; Lemstra AW; van de Berg WDJ; Teunissen CE
    Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32806791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.
    Wennström M; Surova Y; Hall S; Nilsson C; Minthon L; Hansson O; Nielsen HM
    PLoS One; 2015; 10(8):e0135458. PubMed ID: 26270969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies.
    Nielsen HM; Hall S; Surova Y; Nägga K; Nilsson C; Londos E; Minthon L; Hansson O; Wennström M
    J Alzheimers Dis; 2014; 40(2):343-50. PubMed ID: 24448788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromogranin A Analysis in the Differential Diagnosis Across Lewy Body Disorders.
    Gmitterova K; Varges D; Schmitz M; Zafar S; Maass F; Lingor P; Zerr I
    J Alzheimers Dis; 2020; 73(4):1355-1361. PubMed ID: 31929170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease.
    Tateno F; Sakakibara R; Kawai T; Kishi M; Murano T
    Alzheimer Dis Assoc Disord; 2012; 26(3):213-6. PubMed ID: 22037599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia.
    Andersson M; Zetterberg H; Minthon L; Blennow K; Londos E
    Int J Geriatr Psychiatry; 2011 Jan; 26(1):100-5. PubMed ID: 21157855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia.
    Maetzler W; Tian Y; Baur SM; Gauger T; Odoj B; Schmid B; Schulte C; Deuschle C; Heck S; Apel A; Melms A; Gasser T; Berg D
    PLoS One; 2012; 7(10):e48042. PubMed ID: 23133543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration.
    Yasui K; Inoue Y; Kanbayashi T; Nomura T; Kusumi M; Nakashima K
    J Neurol Sci; 2006 Dec; 250(1-2):120-3. PubMed ID: 17005202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.
    Abdi F; Quinn JF; Jankovic J; McIntosh M; Leverenz JB; Peskind E; Nixon R; Nutt J; Chung K; Zabetian C; Samii A; Lin M; Hattan S; Pan C; Wang Y; Jin J; Zhu D; Li GJ; Liu Y; Waichunas D; Montine TJ; Zhang J
    J Alzheimers Dis; 2006 Aug; 9(3):293-348. PubMed ID: 16914840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased albumin CSF/serum ratio in dementia with Lewy bodies.
    Llorens F; Schmitz M; Gloeckner SF; Kaerst L; Hermann P; Schmidt C; Varges D; Zerr I
    J Neurol Sci; 2015 Nov; 358(1-2):398-403. PubMed ID: 26476775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.